Tonix Pharmaceuticals Reports Positive Immune Response Results from COVID-19 Vaccine Candidate TNX-1800, Following Vaccination of Non-Human PrimatesGlobeNewsWire • 11/16/20
Tonix Pharmaceuticals Outlines New Statistical Method to Analyze Future PTSD Studies at the 3rd Annual Neuropsychiatric Drug Development SummitGlobeNewsWire • 11/12/20
Tonix Pharmaceuticals to Present at 3rd Annual Neuropsychiatric Drug Development SummitGlobeNewsWire • 11/09/20
Tonix Pharmaceuticals Reports Third Quarter 2020 Financial Results and Operational HighlightsGlobeNewsWire • 11/09/20
Tonix Pharmaceuticals Enrolls First Participant in the PRECISION Study, an Observational Study to Facilitate Development of Precision Medicine Techniques for COVID-19 Vaccines and TherapeuticsGlobeNewsWire • 10/15/20
Tonix Pharmaceuticals Announces Plan to Complete the Phase 3 RELIEF Study of TNX-102 SL for Management of Fibromyalgia with Currently Enrolled Participants Based on Results of Interim AnalysisGlobeNewsWire • 09/29/20
Tonix Pharmaceuticals Completes Purchase of Facility to House Advanced Development Center (ADC) for Vaccine ProgramsGlobeNewsWire • 09/28/20
Tonix Pharmaceuticals to Host Live Webinar: Antibody vs. T Cell Immunity: Is a Single Vaccine Enough to Stop COVID-19?GlobeNewsWire • 09/17/20
Tonix Pharmaceuticals Enrolls First Patient in COV-LOGIC, an Observational Study to Assess Antibody and T Cell Responses to SARS-CoV-2, the Virus that Causes COVID-19GlobeNewsWire • 09/15/20
Tonix Pharmaceuticals Initiates Enrollment in Second Potentially Pivotal Phase 3 Study, the RALLY Study, of TNX-102 SL for the Management of FibromyalgiaGlobeNewsWire • 09/03/20
Tonix Pharmaceuticals to Participate in Upcoming September Virtual Investor ConferencesGlobeNewsWire • 08/27/20
Tonix Pharmaceuticals Reports Second Quarter 2020 Financial Results and Operational HighlightsGlobeNewsWire • 08/10/20
Tonix Pharmaceuticals Announces Clearance of IND for TNX-102 SL for Treatment of Alcohol Use DisorderGlobeNewsWire • 08/06/20
Tonix Pharmaceuticals Holding Corp. Announces Rescheduling of Special Meeting of StockholdersGlobeNewsWire • 07/21/20
Tonix Pharmaceuticals Announces Research Collaboration to Develop Precision Medicine Techniques for COVID-19 Vaccines and TherapeuticsGlobeNewsWire • 07/16/20
Tonix Pharmaceuticals Holding Corp. Closes $10.5 Million Common Stock Registered Direct OfferingGlobeNewsWire • 07/15/20
Tonix Pharmaceuticals Enters into Research and Exclusive License Option Agreement with Kansas State University to Develop Vaccine Against COVID-19GlobeNewsWire • 07/13/20
Tonix Pharmaceuticals Completes Enrollment in Phase 3 RELIEF Trial of TNX-102 SL for Management of FibromyalgiaGlobeNewsWire • 07/10/20